Atara Biotherapeutics Raises $52M

Thousand Oaks-based Atara Biotherapeutics announced this morning that it is in a second close of its Series B funding round, bringing its total raised in the funding to $52M. According to Atari Biotherapeutics, the investors in the round included Alexandria Venture Investments, Amgen Ventures, The Baupost Group, Celgene Corporation (Nasdaq: CELG), DAG Ventures, Domain Associates, EcoR1 Capital and Kleiner Perkins Caufield & Byers. Atara is developing a number of biotherapeutics, including a treatment for protein energy wasting (PEW) and a treatment for ovarian cancer and other solid tumors. More information »